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Abstract
Background—Graft-versus-host-disease (GVHD) is a severe and frequent complication of
allogeneic bone marrow transplantation (BMT) that involves the gastrointestinal tract and lungs.
The pathobiology of GVHD is complex and involves immune cell recognition of host antigens as
foreign. We hypothesize a central role for the collectin surfactant protein A (SP-A) in regulating
the development of GVHD after allogeneic BMT.
Methods—C57BL/6 (H2b; WT) and SP-A deficient mice on C57BL/6 background (H2b; SP-
A−/−) mice underwent allogeneic (Allo) or syngeneic (Syn) BMT with cells from either C3HeB/
FeJ (H2k; SP-A−/−alloBMT or WTalloBMT) or C57Bl/6 (H2b; SP-A−/−synBMT or WTsynBMT)
mice. 5 weeks post BMT, mice were necropsied and lung and gastrointestinal (GI) tissue were
analyzed.
Results—SP-A−/−alloBMT or WTalloBMT had no significant differences in lung pathology
however, SP-A−/−alloBMT mice developed marked features of GI GVHD including decreased
body weight, increased tissue inflammation and lymphocytic infiltration. SP-A−/−alloBMT mice
also had increased colon expression of IL-1β, IL-6, TNF-α, and IFN-γ and as well as increased
Th17 cells, and diminished regulatory T (Treg) cells.
Conclusions—Our results demonstrate the first evidence of a critical role for SP-A in
modulating GI GVHD. In these studies, we demonstrate that mice deficient in SP-A that have
undergone an alloBMT have a greater incidence of GI GVHD that is associated with increased
Th17 cells and decreased Tregs. The results of these studies demonstrate that SP-A protects
against the development of GI GVHD and establishes a role for SP-A in regulating the immune
response in the GI tract.
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Approximately 50,000 patients worldwide undergo bone marrow transplantation (BMT)
each year for treatment of both malignant and non-malignant disorders (1). Despite the use
of potent immunosuppression, graft-versus-host disease (GVHD) is a frequent complication
of allogeneic BMT resulting in significant morbidity and mortality. GVHD typically
involves the gastrointestinal (GI) tract, skin, and lungs (2). The specific mechanisms of how
GVHD is initiated remain poorly characterized. However, a major component of GVHD is
the presence of a milieu of proinflammatory cytokines such as IL-1, TNF-α, IFN-γ, and
IL-6 that can lead to tissue damage (3). These cytokines have been shown to influence naïve
donor T cell differentiation into proinflammatory T cell populations such as Th1 and Th17
(4). In addition, GVHD is often associated with failure to develop regulatory T cells (Treg),
a specialized subpopulation of T cells which suppresses activation and/or extent of the
proinflammatory T cell response, at mucosal surfaces, such as the GI tract, (5–7). The strong
association between proinflammatory cytokine production and the absence of Treg cells
during GVHD suggests that one mechanism by which to inhibit the detrimental effects
associated with GVHD is to control the inflammation associated with tissue damage to
thereby alter the T cell response.
The collectin surfactant protein A (SP-A) was first recognized as a molecule important in
pulmonary host defense and homeostasis, but has recently been identified in other mucosal
organs such as the uterus, eye, small intestine and colon (8–11). Genetic polymorphisms that
change the expression levels of surfactant proteins have been implicated in extrapulmonary
disease pathology. Recent studies identified specific SP-A haplotypes associated with
increased susceptibility of children to recurrent otitis media (12), time to parturition (13),
while other collectins such as SP-D appear to be important for clearing GI pathogens (14)
and in susceptibility to Crohn's disease (15). These studies suggest that the expression of
surfactant proteins in extrapulmonary mucosal surfaces is important to host defense. SP-A is
also important in regulating the production of proinflammatory cytokines by immune cells.
Multiple studies have reported that in the absence of SP-A there is a significant increase in
pulmonary production of inflammatory cytokines such as TNF, IFN-γ, and IL-6 after
pathogen challenge (16, 17). SP-A has also been shown to influence adaptive immune
responses in pulmonary diseases by decreasing dendritic cell maturation and T cell
proliferation (18–22). Taken together, SP-A is an important mediator of mucosal
inflammation and immunity and may have a functional role in the development of GVHD
after BMT.
Herein we show that mice deficient in SP-A have a greater incidence and severity of colonic
GVHD due to the potentiation of allogeneic T cell activation, increased Th17 cells in the GI
tract, and decreased production of Treg cells. These data expand on the evolving literature
suggesting extensive functional roles for surfactant proteins in extrapulmonary disease
pathology. The data suggests that SP-A has an important immunological role in the
prevention of gastrointestinal GVHD after BMT.
MATERIALS AND METHODS
Mice
Experiments were approved by the Duke Institutional Animal Care and Use Committees.
Male 8–10 week-old C57BL/6 (H2b; WT) and SP-A deficient mice were maintained on
C57BL/6 background (H2b;SP-A−/−). C3HeB/FeJ (H2k;allogeneic) or C57BL/6
(H2b;syngeneic) mice were used as donors and were obtained from the Jackson Laboratories
(Bar Harbor, ME). All animals were housed in a pathogen-free facility on LPS-free bedding
(Shepherd Specialty Papers Inc., Kalamazoo, MI), with irradiated food (PicoLab Mouse Diet
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20-5058, Purina Mills, Richmond, IN) and antibiotic water (Sulfamethoxazole/
Trimethoprim 1.2/0.24mg/mL) after BMT.
Murine bone marrow transplantation
Donor mice were euthanized using CO2. Tibia and femur bone marrow and splenocytes
were isolated, filtered twice through 70µm filters (BD Biosciences, Franklin Lakes, NJ),
counted, and resuspended in RPMI 1640 media containing 10% FBS (Hyclone, Logan, UT),
1% L-Glutamine (Sigma-Aldrich, St. Louis, MO) and 1% Penicillin/Streptomycin (Sigma-
Aldrich). Recipient (WT or SP-A−/−) mice were lethally irradiated using a Cesium irradiator
(9.25 Gy) and injected via retro-orbital route with 4×106 bone marrow cells and 1×106
splenocytes. Engraftment was evaluated 4 weeks post-transplantation using peripheral blood
flow cytometry with anti-H2Db-FITC (clone KH95) and anti-H2Kk-PE (clone 36-7-5) (BD
Biosciences). Animals were >95% engrafted with donor-derived cells.
Histologic Assessment of Acute Graft Versus Host Disease
The presence of acute GVHD was assessed by detailed morphologic analysis of lung, liver,
distal small intestine, proximal large intestine and rectum necropsy specimens. The
specimens were harvested from mice 5 weeks post BMT and fixed in fresh neutral buffered
formalin. Following fixation, the specimens were embedded in paraffin, cut into 5 µm thick
sections and stained with hematoxylin and eosin (H&E). The slides were coded with a
unique number that had no reference to mouse type or treatment status and graded by a
single blinded pathologist (D.M.C for GI samples, S.M.P for lung samples). For samples of
the GI tract (liver, distal small intestine, proximal large intestine and rectum) a
semiquantitative scoring system was used to document the presence and severity of various
GVHD associated morphologic features (23, 24). The specific parameters scored are listed
in Table I. A grade was given for each parameter was as follows: 0 as normal, 0.5 as focal
and rare, 1 as focal and mild, 2 as diffuse and mild, 3 as diffuse and moderate, and 4 as
diffuse and severe. The grades were subsequently added to provide a total score for each
specimen. For lung samples pathological severity of lymphocytic lung inflammation was
graded on a 9-point scale as described previously (25).
CD3+ Immunohistochemistry
CD3 immunohistochemistry was performed with rabbit anti-mouse CD3 antibody (Thermo
Scientific, Fremont, CA) used at a dilution of 1:150 and developed with horseradish
peroxidase-conjugated streptavidin (Vector Laboratory, Burlingame, CA) and then
diaminobenzidine (Dako, Carpinteria, CA). To quantify the amount of intraepithelial
lymphocytes, the most densely inflamed areas (away from prominent lymphoid follicles)
were identified for each colon sample. The number of CD3 positive intraepithelial
lymphocytes were counted in 10 consecutive fields at 400× magnification and averaged per
sample.
RNA analysis
After necropsy, tissue samples were preserved in RNAlater (Ambion/Applied Biosystems,
Austin, TX). RNA was extracted (Ambion/Applied Biosystems): quantity was measured
spectrophotometrically and quality was analyzed using Bio-RAD Experion chips (Bio-Rad
Laboratories). For additional transcript analysis, cDNA was transcribed using high-capacity
cDNA reverse transcription kit (Applied Biosystems, Foster City, CA). 50ng of cDNA was
used for qPCR (in triplicate) using Taqman probe-and-primer combinations for IL-6
(Mm00475162_m1), IL-1β (Mm01336189_m1), IFN-γ (Mm01168134_m1), and the
endogenous β-actin (4352933) (Applied Biosystems). Ct values were determined using ABI
7500 Real Time PCR System with SDS software 1.3.1. Change in expression was calculated
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using the 2−ΔΔCt method normalized to β-actin expression and expressed as fold-change
compared to the control group.
Serum ELISA
Blood was harvested 5 weeks post BMT and murine TNF-α levels were measured in serum
with a cytokine-specific enzyme-linked immunosorbent assay kit (R&D Systems,
Minneapolis, MN).
Peyer’s patches and mesenteric lymph node flow cytometry
Peyer’s patches and mesenteric lymph node were isolated, filtered through a 70µm filter
(BD Biosciences), washed, and resuspended in PBS with 3% FBS, 0.05% sodium azide
(VWR International, West Chester, PA), and 10mM EDTA. Live cells were counted using
0.4% Trypan-Blue (Sigma-Aldrich) dead-cell exclusion. Cells were blocked using 5%
normal-mouse-serum, 5% normal-rat-serum (Jackson ImmunoResearch Laboratories Inc.,
West Grove, PA), and 1% Fc-receptor-block (anti-mouse CD16/32) (eBioscience, San
Diego, CA). For intracellular cytokine staining, cells were stimulated with 50 ng/ml phorbol
myristate acetate and 500 ng/ml ionomycin (Sigma) for 4 hours before staining and
incubated with GolgiStop (BD Biosciences) during the last 3 hours of stimulation. Cells
were fixed and permeabilized using Cytofix/Cytoperm (BD Biosciences) and labeled with
antibodies against IL-17A-PE (clone eBio17B7, eBioscience) and IFN-γ-APC (clone
XMG1.2, eBioscience). For staining of surface antigens, cells were labeled with anti-mouse
anti-CD3-FITC, anti-CD8-PE-Cy7, anti-CD11b-APC-Cy7, and anti-CD4-PE-Cy5
(eBioscience). For intracellular staining of transcription factor FoxP3, after surface staining
cells were permeabilized using Cytofix/Cytoperm (BD Biosciences) and then labeled with
anti-FoxP3-PE (clone FJK-16s, eBioscience). Fluorescence was measured using BD
FACSCantoII flow cytometer (BD Biosciences) and analyzed using the FlowJo software
(Tree Star Inc., Ashland, OR): a singlet gate was used to exclude cell aggregates, followed
by an all-cell gate to exclude small debris and dead cells. Cell percentages are expressed as
percentage of all cells and converted to absolute numbers by multiplying by live-cell counts.
Mixed Leukocyte Reaction
T cells from C57BL/6 were isolated from spleens by negative magnetic bead selection (Pan
T cell beads; Miltenyi Biotec Inc., Auburn, CA). Isolated T cells were washed in media,
filtered through 70 µm filters (BD, Franklin Lakes, NJ), counted on a hemocytometer, and
resuspended in RPMI 1640 (Gibco, Grand Island, NY) containing Penicillin/Streptomycin
(Sigma-Aldrich, St. Louis, MO), L-Glutamine (Sigma-Aldrich, St. Louis, MO) and 10%
FBS (Hyclone, Logan, UT). C3HeB/FeJ (allogeneic) or C57BL/6 (syngeneic) 5×105
stimulator splenocytes (irradiated in a Cesium irradiator at 20 Gy) were co-cultured with
5×105 C57Bl/6 responder T cells in the presence of 20µg/ml of exogenous SP-A (purified as
previously described (26)) or 20µg/ml of purified mouse control IgG (Jackson
Immunoresearch, West Grove, PA) for 4 days. 1 uCi of 3H-thymidine was added for the last
18 hours of culture. 4 days following initial culture, splenocytes were harvested (TomTec
harvester 96 Mach III M, Hamden, CT) and radioactivity was measured using a β-counter
(Wallac Trilux 1450 Microbeta counter, Waltham, MA). Results are reported as counts per
minute (cpm) and proliferation was determined by subtracting cpm of responders alone from
cpm in wells containing both responders and stimulators.
Colonic tissue explant cultures
Colonic tissue fragments (0.5 g dry weight) were harvested 5 weeks post BMT and
processed as previously described (27). Tissue-fragment supernatants were collected after 24
h for cytokine analysis. Murine IL-17a levels were measured in supernatants with a
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cytokine-specific enzyme-linked immunosorbent assay kit (R&D Systems, Minneapolis,
MN).
Statistical analysis
Data are expressed as means±SEM. Between-group comparisons were performed to
specifically determine if SP-A−/− BMT mice were significantly different from WT BMT
(allogeneic or syngeneic) mice. Comparisons were performed using a one-way ANOVA in
Graph Pad Prism Software (Version 5.03, La Jolla, CA). P-values of <0.05 were considered
significant. The study was repeated 5 independent times with an n of 5–8 mice per group per
experiment. The data shown here is representative of one study.
RESULTS
SP-A deficiency does not affect development of pulmonary GVHD after BMT
SP-A deficient (SP-A−/−) or sufficient (WT) recipient mice that had undergone BMT with
either allogeneic (alloBMT) or syngeneic (synBMT) donor cells were assessed for
perivascular and peribronchiolar lymphocytic inflammation (Figure 1 and Supplemental
Figure 1). Mice that had not undergone a BMT (nontransplanted; NT), whether deficient
(SP-A−/−) or sufficient (WT) in SP-A, did not have any significant pulmonary pathological
changes. After alloBMT, comparable levels of perivascular and peribronchiolar
inflammation were seen in both SP-A deficient and sufficient (WT) recipient mice (SP-
A−/−alloBMT or WTalloBMT). This trend was also reflected in the BAL cell counts and T
cell infiltration into the airspace (data not shown). Minimal pathology was seen with mice
that had undergone syngeneic BMT (SP-A−/−synBMT or WTsynBMT) (Figure 1 and
Supplemental Figure 1). This data suggested that SP-A does not regulate alloimmune lung
injury after allogeneic bone marrow transplantation.
SP-A deficiency increases the severity of small and large intestine GVHD after allogeneic
BMT
Despite no difference in pulmonary pathology, we did observe that SP-A−/−alloBMT were
only able to regain approximately 85% of starting body weight after transplantation. This
observation was not seen in WTalloBMT, syngeneic, or NT controls. After BMT, all
treatment groups lost approximately 20% of body weight at 2 weeks post transplantation.
WT mice that had undergone an alloBMT and syngeneic controls were able to regain back
to 100% of starting body weight by 4 weeks post BMT (Fig. 2).
Given the severe weight loss in SP-A−/−alloBMT mice, we were interested to examine the
pathology of the gastrointestinal tract to describe a cause for this weight loss. The liver,
small and large intestines were examined for features of gastrointestinal GVHD (Fig. 3A, B,
and D). Within the liver, no significant pathologic alterations were seen in any of the
treatment groups (Fig. 3A). Upon necropsy, SP-A−/−alloBMT mice had increased colonic
wall thickness, decreased length and unformed fecal pellets (Fig. 3C), as well as common
features of GI GVHD such as ulceration, neutrophil infiltration and increase in apoptotic
cells (Supplemental Figure 2A and B). These gross pathologic changes were reflected in
increased gross colon weight of the SP-A−/−alloBMT as compared to WTalloBMT controls
(Fig. 3D). Histologic examination revealed that SP-A−/−alloBMT mice had a significant
increase in inflammation and edema of the musclaris propria and lamina propria in both the
small and large intestine when compared to the WTalloBMT mice (Fig. 3 E–I). However,
injury was more severe in colon than in the small intestine, possibly due to the slower rate of
repair in the large intestine after radiation injury (28). Minimal GI pathology was seen in
SP-A−/−synBMT or WTsynBMT or NT mice (Fig. 3B and E).
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To determine when GI pathology develops after BMT, large intestinal pathology was
assessed at 2, 3, and 4 weeks post-transplant. 2 weeks post alloBMT, both WT and SP-A−/−
recipients has similar colon pathology (Fig. 4). However, at 3 weeks post BMT, SP-
A−/−alloBMT mice had a significant increase in pathology score and this difference was
accentuated at 4 weeks post BMT (Fig. 4). The exacerbated GVHD pathology seen at 4
weeks post BMT was associated with an increase in hallmarks of GVHD such as neutrophil
and lymphocyte recruitment in the colons of SP-A−/−alloBMT that was not seen in
WTalloBMT (data not shown).
SP-A deficiency increases proinflammatory cytokine expression in large intestine after
allogeneic BMT
To identify mediators that may potentiate the GI GVHD seen in SP-A−/−alloBMT mice,
RNA was isolated from the colon and proinflammatory cytokine mRNA expression was
determined by qPCR. In correlation with more severe pathological findings, SP-
A−/−alloBMT mice had a significant increase in TNF-α, IL-1β, IL-6, and IFN-γ mRNA
when compared to WTalloBMT controls (Fig. 5A–D). This increase in cytokine expression
was unique to allogeneic BMT since there was no increase in any of the mediators after
syngeneic BMT in SP-A sufficient or deficient recipients (Fig. 5). The upregulation of
proinflammatory cytokines occurs only in the GI tissue since serum cytokine levels such as
TNF-α were no different in SP-A deficient recipients when compared to sufficient controls
(Fig. 5E).
SP-A deficiency increases lymphocytic inflammation in large intestine after allogeneic
BMT
Since GVHD is also associated with the development of excessive T cell inflammation (3, 7)
and SP-A has previously been shown to influence T cell proliferation (29, 30), it was of
interest to identify if SP-A attenuates T cell alloproliferation and tissue infiltration. To
determine if SP-A can influence allogeneic T cell proliferation, a mixed lymphocyte reaction
(MLR) in the presence of exogenous SP-A was performed. Allogeneic T cell proliferation
was decreased in the presence of SP-A when compared to media with IgG. Syngeneic T cell
proliferation was minimal and no difference was seen with the addition of exogenous SP-A
(Fig. 6A). To examine if this effect was seen in vivo, large intestine sections were stained
for CD3+ cells and quantified as previously described. After alloBMT, SP-A deficient
recipients had a significant increase in intraepithelial and lamina propria CD3+ T cells
(Figure 6B and Supplemental Figure 3). Minimal CD3+ T cell infiltration was seen in
WTalloBMT, SP-A−/−synBMT, and WTsynBMT (Figure 6B and Supplemental Figure 3
and data not shown, respectively).
SP-A deficiency increases CD4 and CD8 T cells in gut- associated secondary lymphoid
tissue after allogeneic BMT
To establish whether or not SP-A deficiency had an effect on CD4 or CD8 T cell numbers in
the secondary lymph node structures of the GI tract, mesenteric lymph nodes (MLNs) and
Peyer’s patches (PPs) were isolated and CD4+ and CD8+ T cell populations were examined
by flow cytometry. Although no differences were noted in the size or number of secondary
lymphoid tissue, SP-A−/−alloBMT mice had a significant increase in the percent and total
number of CD4+ and CD8+ T cells in the MLNs and PPs when compared to WTalloBMT
mice (Fig. 7A and B; Supplemental Figure 4).
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SP-A deficiency decreases Tregs and increases Th17 cells in gut-associated lymphoid
tissue after allogeneic BMT
Since CD4+ T cells have been implicated in the development of GVHD (31), we wanted to
determine if there was a difference in T cell polarization in secondary lymph node structures
after alloBMT in SP-A deficient recipients. WTalloBMT mice had approximately 18% (18 ±
3.2) of CD4+ T cells that were CD25+FoxP3+ (Tregs) in the MLNs and 12% (12 ± 1.3) of
CD4+ T cells in PPs (Fig. 8C and D). However, when recipients were deficient in SP-A,
Tregs were decreased to approximately half (MLN 10% ± 1.8; PP 7% ± 1.6) of what was
seen in WTalloBMT mice (Fig. 8A and B). This decrease was not seen in the MLNs or PPs
of SP-A−/−synBMT mice when compared to WTsynBMT (data not shown). These trends
were also reflected in the absolute numbers of Tregs in the MLNs and PPs (Fig. 8E).
Th17 cells have been associated with the severity of GVHD (31, 32), therefore, we
examined whether or not SP-A deficiency is associated with the development of Th17 cells
in the secondary lymphoid structures of the GI tract. After WTalloBMT, CD3+CD4+IL-17+
(Th17) cells were not readily identified within the MLNs or PPs (Fig. 9C and D). However,
in MLNs and PPs of SP-A−/−alloBMT, approximately 5% of CD4+ T cells produced IL-17
(Fig. 9A and B). The presence of Th17 cells was not seen in either secondary lymphoid
structure after synBMT in SP-A sufficient or deficient recipients (data not shown). The
increase in Th17 cells in the MLNs and PPs after alloBMT in SP-A sufficient and deficient
recipients was also confirmed in the absolute number of Th17 cells (Fig. 9E). Colon explant
cultures for IL-17a also reflected a similar trend with a significant increase in tissue
production as seen in the secondary lymphoid structures from SP-A−/−alloBMT when
compared to WT and syngeneic controls (Fig. 9F). Together, these data suggest that there is
an alteration in T cell polarization towards Th17 and away from regulatory T cells in SP-A
deficient mice after allotransplant, which may predispose them to the development of GI
GVHD.
DISCUSSION
GVHD pathophysiology is complex and not well understood, but is critically dependent on
the differentiation of donor-derived T cells into proinflammatory subsets (3, 33) leading to
marked tissue injury, morbidity and mortality. This morbidity and mortality persists despite
aggressive immunosuppressive regimens, which suggest that inflammatory pathways exist
in this disease process, that are poorly responsive to standard immunosuppressive regimens.
The failure of standard immunosuppressive regimens necessitates an understanding of
specific mechanisms by which the host develops GVHD after bone marrow transplant in
order to effectively treat GVHD. We present, in this current study, novel data that suggest
that SP-A protects against the development of GI GVHD presumably by a reduction in the
production of proinflammatory cytokines. In addition, we highlight a potential mechanistic
role for SP-A in maintaining specific T cell polarization in mucosal tissues after alloBMT.
The enhanced allogeneic T cell proliferation and exacerbated GI pathology in the SP-A
deficient mice was unexpected in light of what is known about SP-A expression and
production. Classically, SP-A is defined as a principle component of the lung alveolar lining
fluid. For this reason, we expected to observe enhanced lung injury after allogeneic BMT in
SP-A deficient recipients. Contrary to this expectation, SP-A deficient recipients did not
have observable lymphocytic inflammation consistent with enhanced pulmonary GVHD in
our model. This lack of exacerbated pulmonary GVHD in SP-A deficient recipients could be
explained by compensation from the other collectins such as SP-D. Previous reports using
an idiopathic pneumonia syndrome model (IPS) have noted that recipient mice lacking SP-A
or both SP-A and SP-D have a significant increase in lung disease after an allogeneic BMT
with a higher dose of T cells (34–37). The IPS model used in the previous studies not only
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used a much higher dose of T cells at the time of BMT than the model presented here. Also,
a chemotherapeutic agent to condition the mice and a different route of injection for
transplantation was used. Any of these factors could account for the variations in pulmonary
pathology in SP-A deficient mice.
Despite the lack of pulmonary pathology, SP-A deficient recipients in the current study
clearly developed enhanced morbidity after BMT as evidenced by profound weight loss.
This suggested that GVHD was occurring in other organ systems. We made the novel
observation that allogeneically transplanted SP-A deficient mice developed pathology in
both the small and large intestine and cytokine production consistent with GI GVHD.
Despite the predominant expression within the lung, SP-A expression is present at
extrapulmonary tissues though at lower levels than seen in the lung (38). Prior work
suggests that collectins are present in the GI system and appear to have a role in the
prevention of intestinal inflammation and pathology (39–45). Murray et al. (46)
demonstrated that a lack of SP-D in the gastric mucosa significantly increased incidence of,
and inflammation associated with, Helicobacter pylori infection (14). Human SNPs in SP-D
have also been associated with susceptibility to Crohn's disease (47). These works also
indicate that SP-D may not be present in the GI tract to compensate for SP-A deficiency,
though this hypothesis was not tested in the reported experiments. Despite the data on SP-D
in GI pathology, less is known about a functional role for SP-A in the intestines. A recent
study examined the immunoregulation by SP-A in the intestines. George et al. identified that
neonatal mice deficient in SP-A had significant intestinal inflammation and pathology after
endotoxin exposure (43). This data and ours cumulatively suggest that surfactant proteins
regulate inflammation and adaptive immunity in the GI system.
One limitation of the present work is that we are unable to reliably identify SP-A in the
intestines of mice. Epithelial cells in the intestines of rats and humans have been shown to
produce both SP-A mRNA and protein (9, 10). This protein has the same charge and
molecular weight as the SP-A found in the lungs. As a result of similarities among collectins
as well as containing major blood group antigenic epitopes (48), the reliability of detecting
SP-A poses a challenge and is difficult based on current available reagents. In our hands, we
were able to detect transcripts for SP-A in the GI tract, but were not able to discern SP-A
versus other collectins in the GI tract (data not shown) using previously established
protocols. However, there is a body of literature that identified SP-A in other tissues besides
the lung and which demonstrate that deficiencies of this protein leads to extrapulmonary
diseases (42, 45, 49, 50) supporting the protective role of SP-A in multiple organs. The
mechanism by how SP-A regulates susceptibility to GI GVHD could be an indirect effect
(spillover of inflammation from the lung) or a local effect (production by the GI tract). We
favor the local effect since serum cytokines were unaltered and the lungs of the SP-
A−/−alloBMT mice had no significant changes in pathology, cell counts, or T cell infiltrates.
An indirect effect could be considered since SP-A does have an important role in controlling
inflammation and T cell proliferation in other organs although our findings do not support
this thus far.
SP-A has been reported to influence both innate and adaptive immune responses. Mice
lacking SP-A challenged with respiratory pathogens have not only delayed clearance but
also significant increase in proinflammatory cytokines such as IL-6 and TNF-α by alveolar
macrophages (51–53), as well as enhanced antigen presenting cell (APC) recruitment and
maturation (54). SP-A has also been shown to influence adaptive immune responses by
preventing T cell proliferation (55) and influencing pulmonary phenotypes (19), through
interaction with not only T lymphocytes but also APCs (20). We extend these observations
by demonstrating that SP-A is important for limiting the expansion of lymphocyte
populations after allogeneic bone marrow transplantation. We also identify that there is a
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preferential polarization from Tregs to Th17 cells in the SP-A deficient recipients. Recent
studies have shown that in vitro differentiated Th17 cells can mediate acute GVHD with
severe pathology in the mucosal organs (32). The mechanism of graft tolerance has also
been shown to involve Treg cells and their capability to confer immune tolerance of allo- as
well as auto-antigens (56). Therefore, the balance between Th17 and Tregs appear to be
critical for immune response responsible for GVHD. Our data suggests that decreased SP-A
levels or function in the GI tract may allow excessive APC maturation and increased
allogeneic T lymphocyte response, promoting the elaboration of proinflammatory cytokines
and thereby causing GI GVHD.
In conclusion, our findings in this study describe an entirely novel role for SP-A in
regulating the immune response in the development of GI GVHD. Although our current
study did not determine the precise mechanisms of how SP-A influences the development of
GI disease after allogeneic BMT, the presence of increased Th17 cells in the GI tract in
association with a subsequent decrease in regulatory T cells suggests a potential role for SP-
A in influencing these T cell subsets in extrapulmonary tissues. Restoring SP-A specifically
in the GI tract may be a viable approach to pursue in future studies in an attempt to develop
new avenues for treating patients and reducing the burden of GVHD after BMT.
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SP-A−/− alloBMT SP-A deficient recipient mice that have undergone an allogeneic
BMT
SP-A−/− synBMT SP-A deficient recipient mice that have undergone a syngeneic BMT
WTalloBMT SP-A sufficient recipient mice that have undergone an allogeneic
BMT
WTsynBMT SP-A sufficient recipient mice that have undergone a syngeneic BMT
NT nontransplanted
Treg regulatory T cells
Th17 T cells producing IL-17
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FIGURE 1. Surfactant Protein A (SP-A) deficiency does not affect the development of
pulmonary GVHD after allogeneic BMT
SP-A deficient (SP-A−/−) or sufficient (WT) mice were reconstituted with cells from
allogeneic (alloBMT) or syngeneic (synBMT) mice and sacrificed 5 weeks after transplant.
Lung pathology was evaluated and pathology grades were determined in a blinded fashion
using a semi-quantitative scoring system based on the thickness of perivascular and
peribronchiolar inflammation as well as the overall percentage of lung involved. (A)
Representative histology of lymphocytic perivascular and peribronchiolar inflammation (B–
E) (H&E stain, 100×) (B) SP-A−/−alloBMT; (C) WTalloBMT (D) SP-A−/−synBMT; (E)
WTsynBMT; (graph is representative of 1 experiment n=5–8/group, data was replicated in 5
independent experiments).
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FIGURE 2. Surfactant Protein A (SP-A) deficiency decreases body weight regain after allogeneic
BMT
Percent of starting body weights after BMT at weeks 1, 2, 3, 4, and 5 post transplant (* = p-
value less than 0.05, ** = p-value less than 0.001) (graph is representative of 1 experiment
n=5–8/group, data was replicated in 5 independent experiments).
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FIGURE 3. SP-A deficiency exacerbates features of gastrointestinal GVHD after allogeneic BMT
SP-A deficient (SP-A−/−) or sufficient (WT) mice were reconstituted with cells from
allogeneic (alloBMT) or syngeneic (synBMT) mice and sacrificed 5 weeks after transplant.
Liver, small intestine and colon pathology was evaluated and pathology grades were
determined in a blinded fashion using a semi-quantitative scoring system described in table
I. Quantitative scoring of (A) liver pathology; (B) small intestine; and (E) colon 5 weeks
post BMT. (C) Gross pathology of SP-A−/−alloBMT (left panel) and WTalloBMT (right
panel). (D) Weights of colons 5 weeks post BMT. (F–I) Representative colon histology
sections are shown for alloBMT groups (H&E stain, 40×) (F) SP-A−/−alloBMT; (G)
WTalloBMT; (H&E stain, 200×) (H) SP-A−/−alloBMT; (I) WTalloBMT. (* = p-value less
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than 0.05, *** = p-value less than 0.0001) (graph is representative of 1 experiment n=5–8/
group, data was replicated in 5 independent experiments).
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FIGURE 4. SP-A deficiency leads to features of gastrointestinal GVHD after allogeneic BMT by
week 3 post BMT
SP-A deficient (SP-A−/−) or sufficient (WT) mice were reconstituted with cells from
allogeneic (alloBMT) or syngeneic (synBMT) mice and sacrificed at 2, 3, and 4 weeks after
transplant. Colon pathology was evaluated at all time points and pathology grades were
determined in a blinded fashion using a semi-quantitative scoring system described in table
I. (*** = p-value less than 0.0001, ns= not significant) (graph is representative of 1
experiment n=5–8/group, data was replicated in 5 independent experiments).
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FIGURE 5. Surfactant Protein A (SP-A) deficiency promotes the upregulation of
proinflammatory cytokine RNA in the colon after allogeneic BMT
5 weeks after BMT, colon tissue was analyzed by real time PCR for cytokine expression.
(A) TNF-α (B) IL-1β (C) IL-6 and (D) IFN-γ transcripts. (* = p-value less than 0.05, *** =
p-value less than 0.0001) (graph is representative of 1 experiment n=5–8/group, data was
replicated in 5 independent experiments).
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FIGURE 6. SP-A deficiency leads to excessive T cell proliferation in the colon after allogeneic
BMT
(A) Mixed lymphocyte reaction with T cells isolated from spleens of C3BFeJ mice (2×10^6
cells/ml, allo T cells) or C57Bl/6J mice (syn T cells) and stimulated with irradiated
splenocytes from C57Bl/6J mice (5×10^6 cells/ml) and cultured in media or media plus 20
ug/ml of exogenous human SP-A. Proliferation was assessed by 3H incorporation and
expressed as counts per minute (cpm). SP-A deficient (SP-A−/−) or sufficient (WT) mice
were reconstituted with cells from allogeneic (alloBMT) or syngeneic (synBMT) mice and
sacrificed 5 weeks after transplant. Colon tissue was stained for CD3+ cells. Lymphocyte
infiltration was quantified by averaging 10 400× fields in a blinded fashion. (B) Average
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number of CD3+ cells in colon in a 400× field of all groups; (C–F) Representative CD3+
staining of colon sections are shown for alloBMT groups (CD3+ stain, 40×) (C) SP-
A−/−alloBMT; (D) WTalloBMT; (CD3+ stain, 400×) (E) SP-A−/−alloBMT; (F)
WTalloBMT. (* = p-value less than 0.05) (graph is representative of 1 experiment n=5–8/
group, data was replicated in 5 independent experiments).
Gowdy et al. Page 21













FIGURE 7. SP-A deficiency increases the number of CD4 and CD8 T cells in mesenteric lymph
nodes and Peyer’s patches after allogeneic BMT
5 weeks after BMT, mesenteric lymph nodes and Peyer’s patches were isolated and
analyzed by flow cytometry for T cell phenotypes. (A) Absolute numbers of CD4+ T cells in
MLNs and PPs; (B) Absolute numbers of CD8+ T cells in MLNs and PPs; (* = p-value less
than 0.05) (graph is representative of 1 experiment n=5–8/group, data was replicated in 3
independent experiments).
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FIGURE 8. SP-A deficiency decreases regulatory T cell differentiation in the gastrointestinal
tract after allogeneic BMT
After BMT, mesenteric lymph nodes (MLNs) and Peyer’s patches (PPs) cells were isolated
and cells were analyzed by flow cytometry. (A–D) Representative flow cytometric plots
show CD3+CD4+CD25+FoxP3+ (Treg) populations for each experimental group (A) SP-
A−/−alloBMT; (B) WTalloBMT; (PPs) (C) SP-A−/−alloBMT; (D) WTalloBMT; (E)
Absolute numbers of Treg cells in MLNs and PPs. (** = p-value less than 0.001, *** = p-
value less than 0.0001) (graph is representative of 1 experiment n=5–8/group, data was
replicated in 3 independent experiments).
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FIGURE 9. SP-A deficiency promotes Th17 cell polarization in the gastrointestinal tract after
allogeneic BMT
After BMT, mesenteric lymph nodes (MLNs) and Peyer’s patches (PPs) cells were isolated
and cells were analyzed by flow cytometry. (A–D) Representative flow cytometric plots
show CD3+CD4+IL-17+ (Th17) populations for each experimental group (MLNs) (A) SP-
A−/−alloBMT; (B) WTalloBMT; (PPs) (C) SP-A−/−alloBMT; (D) WTalloBMT; (E)
Absolute numbers of Th17 cells in MLNs and PPs. (F) IL-17a production by colon explant
cultures were measured by ELISA at 24hrs post-harvest. (* = p-value less than 0.05) (graph
is representative of 1 experiment n=5–8/group, data was replicated in 3 independent
experiments).
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Table I
A semiquantitative scoring system was used to document the presence and severity of various GVHD
associated morphologic features.
LIVER SMALL AND LARGE BOWEL
Portal Triads Architecture
   Portal tract expansion    Villus blunting
Bile Ducts/Ductules    Crypt regeneration
   Mononuclear infiltrate of epithelium    Ulceration
   Pyknotic/apoptotic duct cells    Lamina propria inflammation
   Intraluminal epithelial cells    Crypt loss
Vascular Epithelial Cytology
   Endothelialitis    Apoptosis
   Mononuclear cells around CV    Sloughing into lumen
Hepatocellular Damage    Lymphocytic infiltrate
   Confluent necrosis    Neutrophilic infiltrate
   Acidophilic bodies Vascular
   Mitotic figures    Edema
   Neutrophil accumulations
   Macrophage aggregates
   Cholestasis
   Steatosis
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